探索脂质纳米粒子发展的挑战:体外-体外相关性差距
Sarah Lindsay1, Muattaz Hussain1, Burcu Binici1
1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.
Vaccines
|May 7, 2025
概括
脂质纳米颗粒 (LNPs) 在体外和体内显示可变的mRNA表达,影响临床翻译. 综合评估对于优化治疗药物和疫苗的LNP输送系统至关重要.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 药物运输 药物运输 药物运输
背景情况:
- 脂质纳米粒子 (LNP) 是核酸的先进输送平台,彻底改变了治疗和疫苗开发.
- 在可靠的体外-体内相关性 (IVIVC) 的挑战阻碍了基于LNP的技术的临床转化.
- 本研究通过评估LNP的物理化学性质,体外疗效和体内性能来解决IVIVC的差异.
研究的目的:
- 调查LNP配方在体外与体内相关性 (IVIVC) 的差异.
- 为了评估不同可离子化脂质对LNP性能的影响.
- 评估LNP在mRNA输送和疫苗应用方面的潜力.
主要方法:
- 使用微流体制造四种LNP配方,它们的离子化脂质不同 (SM-102,ALC-0315,MC3,C12-200).
- 分析了物理化学性质 (大小,PDI,泽塔潜力,封装).
- 在体外mRNA表达被评估在三个细胞系.
- 评估了体内mRNA表达和疫苗的疗效.
主要成果:
- 所有LNP都表现出可比的物理化学特性 (70-100纳米大小,低PDI,高封装).
- 在体外,SM-102 LNP在不朽化和免疫细胞中显示出明显更高的蛋白质表达 (p <0.05).
- 在体内,ALC-0315和SM-102 LNP产生显著更高的蛋白质表达 (p <0.05),它们之间没有差异;MC3和C12-200表达较低.
- 所有LNP配方都引起了与候选疫苗相似的强烈免疫反应.
结论:
- 在LNP发展的相关体外和体内结果中存在显著的变异性.
- 电离性脂质的选择对LNP在体内mRNA的表达有重大影响,但对疫苗的有效性没有影响.
- 整体评估策略对于优化LNP临床转换至关重要.
相关概念视频
Lipid-derived Compounds in the Human Body
5.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.5K
Methods for Studying Drug Absorption: In vitro
845
In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
845
Equivalence: In Vitro and In Vivo Bioequivalence
390
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
390
In Vitro Drug Release Testing: Overview, Development and Validation
600
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
600
Drug Product Performance: In Vitro–In Vivo Correlation
439
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
439
Modified-Release Drug Delivery Systems: Bioavailability
177
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
177


